Parkside Financial Bank & Trust’s Xenon Pharmaceuticals XENE Stock Holding History

Parkside Financial Bank & Trust’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.81K	Hold	30	–	–	﹤0.01%	2216
2026 Q1	$1.75K	Hold	30	–	–	﹤0.01%	2165
2025 Q4	$1.34K	Hold	30	–	–	﹤0.01%	2238
2025 Q3	$1.21K	Hold	30	–	–	﹤0.01%	2212
2025 Q2	$939	Buy	+30	New	+$979	﹤0.01%	2287

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Parkside Financial Bank & Trust's XENE Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 30 shares worth $1.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

Parkside Financial Bank & Trust first reported a position in XENE in Q2 2025 and has held it in 5 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Parkside Financial Bank & Trust held 30 shares of Xenon Pharmaceuticals worth $1.81K as of Q2 2026.
Parkside Financial Bank & Trust left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2216 holding.
Parkside Financial Bank & Trust first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.